A team of researchers, led by Dr. J. Chen, conducted an extensive analysis of DIO2 gene polymorphisms in a cohort of patients with PTC. The objective was to investigate how these genetic variations correlate with both the effectiveness of TSH suppression therapy and the overall well-being of patients. Thyroid cancer treatment involves complex management strategies, with TSH suppression therapy being a cornerstone for preventing cancer recurrence. However, it remains unclear how individual genetic differences might affect the efficacy and tolerability of this therapeutic approach.

DIO2, or deiodinase enzyme type 2, is vital in the metabolism of thyroid hormones, converting the prohormone thyroxine (T4) into the active form triiodothyronine (T3). Genetic polymorphisms in the DIO2 gene can influence the enzymatic activity of deiodinase, potentially leading to variations in thyroid hormone levels in the body. This has implications for patients on TSH suppression therapy since optimal hormonal levels are critical to minimizing the risk of thyroid cancer recurrence and maintaining the patient’s quality of life.

Understanding the prevalence of different DIO2 polymorphisms among patients with PTC is crucial. Researchers collected genetic samples and associated clinical data from a diverse group of PTC patients, looking specifically for certain DIO2 variants known to influence thyroid function. The findings indicated notable frequencies of these polymorphisms within the studied population, which could provide a foundation for tailoring treatment protocols.

The study also delved into the subjective experiences of the participants, emphasizing the importance of quality of life assessments alongside clinical measures. Participants completed validated questionnaires designed to evaluate their well-being, psychological state, and overall life satisfaction, allowing researchers to correlate these subjective reports with genetic data. This dual approach highlights the significance of considering both genetic and psychosocial factors when evaluating treatment outcomes.

In addition to the genetic analysis, the researchers monitored clinical parameters such as TSH levels, thyroid hormone levels, and potential side effects associated with TSH suppression therapy. This comprehensive data collection aimed to assess not only the physiological effects of treatment but also the emotional and psychological ramifications for patients dealing with cancer survivorship. The dual focus on physical and emotional health reflects a broader understanding of cancer treatment that transcends mere survival.

Interestingly, the findings suggested that certain DIO2 polymorphisms might adversely affect quality of life by influencing side effects commonly associated with TSH suppression therapy. Patients with specific genetic profiles reported increased fatigue, anxiety, and depressive symptoms compared to those without such variations. These results underscore the relevance of personalized medicine, which seeks to tailor treatment based on individual genetic makeups, ultimately aiming to improve outcomes and patient satisfaction.

Moreover, the implications of this research extend beyond just papillary thyroid cancer. Understanding how DIO2 polymorphisms function could lead to advancements in managing other thyroid-related disorders and may inform treatment strategies for a broader range of cancers. For instance, integrating genetic testing into clinical practice might allow oncologists to better predict which patients will respond best to TSH suppression therapy and how to minimize side effects.

As the field of personalized medicine continues to evolve, studies like this one play a pivotal role in shaping our understanding of complex interactions between genetics, treatment modalities, and patient experiences. Furthermore, the incorporation of genetic factors into clinical practice holds promise not just for enhancing therapeutic efficacy but also for enriching the overall patient experience throughout their cancer journey.

In conclusion, this research sheds light on the intricate relationship between DIO2 gene polymorphisms, TSH suppression therapy, and quality of life in papillary thyroid cancer patients. As we move forward, it is crucial for further studies to validate these findings and explore the potential for incorporating genetic assessment into routine clinical practice. By doing so, healthcare providers may improve treatment outcomes, reduce adverse effects, and ultimately enhance the lives of those affected by thyroid cancer.

The exploration of genetic factors such as the DIO2 polymorphisms represents a frontier in cancer treatment and patient care, allowing for a more nuanced understanding of how genetic diversity affects therapeutic pathways. As researchers continue to decode the complexities of cancer biology and treatment response, we can expect to see a shift towards more individualized therapeutic strategies and improved patient-centered care in the years to come.

Subject of Research: Impact of DIO2 polymorphisms on quality of life and TSH suppression therapy in patients with papillary thyroid cancer

Article Title: Impact of DIO2 polymorphisms on quality of life and TSH suppression therapy in patients with papillary thyroid cancer

Article References:

Chen, J., Lin, Z., Luo, Y. et al. Impact of DIO2 polymorphisms on quality of life and TSH suppression therapy in patients with papillary thyroid cancer.
BMC Endocr Disord 25, 278 (2025). https://doi.org/10.1186/s12902-025-02085-x

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12902-025-02085-x

Keywords: DIO2 polymorphisms, papillary thyroid cancer, quality of life, TSH suppression therapy, personalized medicine.

The dosage of sacubitril/valsartan is pivotal. While current guidelines suggest a starting dose followed by titration based on patient tolerance, the nuances of individual patient characteristics often complicate this approach. Factors such as renal function, concurrent medications, and the overall clinical profile of a patient play significant roles in determining the most appropriate dose. Hence, the authors argue that a “one-size-fits-all” dosing strategy may not be optimal for every patient, reiterating that personalization should be at the forefront of treatment considerations.

Meta-analyses and observational studies have consistently demonstrated the benefits of sacubitril/valsartan in reducing morbidity and mortality in patients with HFrEF. However, despite its proven efficacy, a significant number of patients remain on suboptimal doses due to barriers such as access, cost, and prescriber hesitancy. This scenario underscores the necessity for more robust frameworks to facilitate the appropriate use of this therapy. Cen and colleagues delve into multiple real-world applications of sacubitril/valsartan and explore the variations in dosing that are frequently reported in clinical practice.

Central to the researchers’ analysis is the concept of “real-world evidence” (RWE) as a critical factor influencing treatment decisions. RWE encompasses data collected outside of the traditional clinical trial setting, providing a rich tapestry of information about drug effectiveness under varied circumstances. By utilizing RWE, the authors emphasized that healthcare providers can glean valuable insights into how sacubitril/valsartan performs across diverse populations, facilitating informed dosing decisions that align better with real patient experiences.

Perhaps one of the most compelling discussions presented by Cen et al. revolves around the implications of underdosing. Numerous studies have indicated that patients who receive lower doses of sacubitril/valsartan experience diminished clinical outcomes compared to those reaching higher doses. This finding raises the question: How can healthcare systems better educate providers on the importance of appropriate dosing? The authors suggest that training programs focused on the nuances of HFrEF treatment may empower healthcare professionals to adopt a more proactive stance when considering sacubitril/valsartan for their patients.

Additionally, the authors touch upon potential barriers to dose escalation, including patient apprehension regarding adverse effects and the intricate dialogue that must occur between providers and patients. Open communication is imperative; addressing concerns around side effects, including hypotension and renal dysfunction, can engender trust and foster adherence to prescribed regimens. The researchers advocate for patient-centered approaches that involve shared decision-making, which can ultimately lead to more successful titration of sacubitril/valsartan dosages.

What’s more, the topic of ongoing monitoring cannot be overstated. Regular follow-up appointments and the use of telemedicine technologies can play a significant role in ensuring that patients on sacubitril/valsartan are closely observed for any complications, as well as for the overall effectiveness of the medication. By staying engaged with patients and adjusting treatment plans based on real-time data, clinicians can improve outcomes significantly. Cen and collaborators suggest that integrated care models that emphasize accountability and patient engagement can transform dose management in everyday practice.

As the body of evidence supporting sacubitril/valsartan continues to grow, future research must consider the factors influencing prescribing patterns among different demographics. Addressing racial and ethnic disparities in medication access and use is critical, as some populations may be more vulnerable to poor outcomes due to inadequate treatment. Delving into the socio-economic aspects of patient populations can yield insights that potentially change how doctors approach dose management across varied groups.

Moreover, the article makes a poignant call to action regarding the need for standardized protocols that encourage consistent dosing practices for sacubitril/valsartan. Establishing such guidelines can help streamline decision-making processes in both hospital and outpatient settings, ultimately promoting better adherence to evidence-based practices among healthcare providers and ensuring optimal patient care outcomes.

In conclusion, the work of Cen, Lin, and Ahmedy illuminates a pivotal aspect of contemporary heart failure management—understanding and optimizing the dosing strategies of sacubitril/valsartan in real-world settings. Their analysis not only highlights the potential benefits of personalized medicine in the treatment of HFrEF, but also prompts critical reflection on current practices and the barriers that inhibit optimal patient outcomes. As the medical community continues to grapple with the complexities of heart failure treatment, embracing individualized dosing strategies and leveraging real-world insights will be essential for improving the lives of patients who rely on therapies like sacubitril/valsartan.

In summary, the pursuit of excellence in heart failure management extends beyond therapeutic agents; it encompasses an understanding of dosing, evidence-based practices, and patient-centric approaches. Through collaboration and dedication to evolving best practices, clinicians can significantly enhance care pathways for individuals battling HFrEF, ensuring that optimal dosing strategies lead the way toward improved survival and quality of life for these patients.

Subject of Research: Optimization of Sacubitril/Valsartan Dosing Strategies in HFrEF

Article Title: Reconsidering Sacubitril/Valsartan Dose Strategies in HFrEF: Evidence and Implications from Real-World Practice-Mini-Review

Article References:

Cen, K., Lin, J. & Ahmedy, F. Reconsidering Sacubitril/Valsartan Dose Strategies in HFrEF: Evidence and Implications from Real-World Practice-Mini-Review.
J GEN INTERN MED (2025). https://doi.org/10.1007/s11606-025-10022-w

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11606-025-10022-w

Keywords: Sacubitril, Valsartan, HFrEF, dosing strategies, real-world evidence, heart failure management

Imerslund-Gräsbeck Syndrome, as described in a recent publication by Makrooni et al., is primarily distinguished by its effects on vitamin B12 absorption, leading to hemolytic anemia and proteinuria. The authors detail the clinical journey of a patient from the Middle East who experienced intermittent proteinuria and anemia over a twelve-year period. This case study not only sheds light on the clinical presentation of the syndrome but also emphasizes the importance of genetic screening and personalized treatment approaches in managing such rare conditions.

One of the most striking aspects of the documented case is the prolonged history leading to diagnosis. The patient experienced intermittent proteinuria and anemia for over a decade, highlighting the often insidious nature of this condition. The lengthy diagnostic odyssey underscores the importance of awareness among healthcare providers about this syndrome. An accurate and timely diagnosis can significantly impact the management and quality of life for affected patients.

The findings presented by Makrooni et al. emphasize the necessity for a multidisciplinary approach in diagnosing rare syndromes such as Imerslund-Gräsbeck. Collaboration among geneticists, pediatricians, and nephrologists is critical for comprehensive patient care. The case report advocates for targeted genetic testing that can reveal underlying mutations associated with the syndrome, ultimately guiding therapeutic decisions and monitoring disease progression in affected individuals.

Further complicating the clinical picture, the case report discusses the interplay between genetic factors and environment. As patients with Imerslund-Gräsbeck Syndrome often exhibit variable clinical manifestations, understanding these differences is crucial for tailoring treatment strategies. It opens discussions on the need for increased genetic counseling and informed discussions regarding potential risks and benefits, especially in regions with limited access to advanced healthcare facilities.

In addition to the clinical and genetic dimensions, the proclaimed awareness of the syndrome needs to be addressed more broadly in the medical community. The implications of untreated or misdiagnosed cases can lead to significant morbidity. The contributions of the authors in sharing their insights not only illuminate the pathophysiology of Imerslund-Gräsbeck Syndrome but also catalyze an essential dialogue about the implementation of better screening practices for anemia and chronic kidney issues.

Moreover, advances in biotechnology and genomic medicine present new frontiers in the understanding and management of genetic syndromes. The exploration of novel therapies aimed at improving vitamin B12 absorption and addressing nephrotoxicity associated with the syndrome raises hope for affected individuals. Future research should focus on gene therapy and other innovative approaches that could potentially alter disease trajectories.

As our understanding of Imerslund-Gräsbeck Syndrome deepens through case studies like this, it becomes clearer that early detection and intervention can significantly alter outcomes. Educating healthcare professionals about this syndrome will promote prompt and effective management, reducing the prevalence of chronic complications associated with delayed treatment. Moreover, public awareness campaigns could serve as a catalyst for individuals presenting with unexplained symptoms to seek treatment sooner.

As this research highlights, the ramifications of genetic disorders extend beyond individual patients. Communities affected by rare conditions such as Imerslund-Gräsbeck Syndrome experience ripple effects, including emotional, social, and financial burdens. By fostering a more informed healthcare ecosystem, we can strive towards better outcomes for families grappling with the challenges inherent in these puzzling syndromes.

The case reviewed in the study underlines the need for continuous education and research in the medical community to unravel the mysteries surrounding such syndromes. More data collection and collaborative research initiatives could further elucidate the prevalence and characteristics of Imerslund-Gräsbeck and similar syndromes, ultimately leading to improved diagnostic protocols and therapeutic interventions.

In summary, the comprehensive examination of Imerslund-Gräsbeck Syndrome presented by Makrooni et al. adds an essential piece to the puzzle of pediatric genetic disorders. The findings from this case study highlight the critical importance of awareness, early diagnosis, and tailored treatments for effectively managing such syndromes. This research signals a step forward in advancing pediatric medicine, ensuring that the unique needs of patients are met with diligence and empathy.

As healthcare continues to innovate, it becomes increasingly imperative to integrate genetic findings into clinical practice. The intersection of genetics with pediatrics promises to unveil new avenues for understanding and treating rare disorders, paving the way for a future where every child receives personalized and effective care based on their genetic makeup.

Subject of Research: Imerslund-Gräsbeck Syndrome, Proteinuria, Anemia

Article Title: Imerslund-Gräsbeck syndrome presenting with a 12-year history of intermittent proteinuria and anemia: a case from the Middle East

Article References:

Makrooni, R., Rahimi Darehbagh, R., Karimi, A. et al. Imerslund-Gräsbeck syndrome presenting with a 12-year history of intermittent proteinuria and anemia: a case from the Middle East.
BMC Pediatr 25, 913 (2025). https://doi.org/10.1186/s12887-025-06284-2

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12887-025-06284-2

Keywords: Imerslund-Gräsbeck Syndrome, Proteinuria, Anemia, Genetic Disorders, Pediatric Medicine, Vitamin B12 Deficiency, Case Study.

The study, spearheaded by a team of researchers including Ong, Chu, and Nurjono, takes a comprehensive look at how hospital-at-home programs can serve as a sustainable solution to the challenges faced by conventional healthcare systems. As urban centers deal with increasing patient loads and limited resources, the need for alternative care models has never been more pressing. Patients often experience elevated levels of stress and discomfort when receiving treatment in traditional hospital settings; this realization has sparked interest in finding better, more personalized alternatives.

This groundbreaking research offers a comparative analysis between traditional hospital care and the multidisciplinary hospital-at-home program. The premise is simple but revolutionary: by providing essential healthcare services at home, patients can receive tailored treatments while enjoying the comfort and familiarity of their own environment. This approach not only improves patient satisfaction but also has the potential to lead to better health outcomes and reduced hospital readmissions.

Importantly, the study emphasizes the value of a multidisciplinary approach. By harnessing the expertise of various healthcare professionals, including nurses, physicians, physiotherapists, and pharmacists, the hospital-at-home program offers a comprehensive level of care. This coordinated strategy ensures that all aspects of a patient’s well-being are addressed, making it more likely for them to achieve optimal health outcomes. Moreover, involving different specialists allows for more individualized care plans, which can be modified according to the patient’s evolving needs.

As participants of the study received care from the multidisciplinary team in their homes, they experienced a significant reduction in the anxiety and confinement associated with traditional hospital stays. Many reported feeling more comfortable and secure, a factor that play an essential role in recovery. Psychological comfort directly influences physical health, and the study’s results support the idea that the home care model can enhance both the mental and emotional welfare of patients.

Moreover, logistical concerns are also positively impacted by such multidisciplinary programs. The time spent on transportation to healthcare facilities can be a burden for many patients, especially the elderly or those with chronic illness. Offering care at home alleviates this issue, allowing patients to avoid time-consuming and often exhausting trips to hospitals. By eliminating transportation issues, the hospital-at-home program not only saves time but also minimizes the potential for exposure to infections commonly found in healthcare settings.

The study analyzes important metrics, including patient satisfaction scores, recovery rates, and the number of hospital readmissions between the two groups—those treated at home versus those treated in traditional settings. Early results indicated a notable decrease in readmissions for the hospital-at-home cohort, which suggests that the model not only enhances patient satisfaction but is also a more effective way to manage chronic conditions. These findings can significantly impact how healthcare is viewed within resource-constrained environments and push the agenda for policy changes.

Another aspect highlighted in the study is the economic advantage of implementing hospital-at-home programs. The healthcare system often faces financial strain due to the high costs associated with prolonged hospital stays. By transitioning patients into a home care model, hospitals can allocate resources more effectively, potentially reducing healthcare expenditures without compromising the quality of care provided. This economic argument may resonate well with healthcare stakeholders who are often looking for ways to cut costs while maintaining high standards of patient care.

As telemedicine technology continues to advance, the integration of digital health tools within the hospital-at-home framework becomes increasingly feasible. Patients can now receive remote consultations, participate in virtual follow-ups, and even use wearable devices to monitor vital signs. Such technological innovations further consolidate the multidisciplinary model and support healthcare providers in delivering timely and effective interventions, ensuring patient safety while streamlining care delivery.

Furthermore, the implications of this study extend beyond individual hospitals and health systems. As countries worldwide grapple with aging populations and escalating healthcare costs, the findings present a scalable model that can be adapted to various healthcare systems across diverse geographical settings. Policymakers and health administrators may look toward the hospital-at-home format as a viable solution to address not only patient needs but also system-wide inefficiencies.

Moving forward, the study underscores the importance of continued research in this domain. A longitudinal approach to evaluate the long-term impacts of these hospital-at-home programs will be necessary to fully understand their effectiveness and sustainability. This might include factors such as long-term health outcomes, patient quality of life, and potential adaptations in clinical guidelines to incorporate this innovative model into standard practice.

Peer-reviewed journals and health organizations will likely take great interest in the findings of this study, which not only provides compelling evidence for adopting hospital-at-home programs but also adds to the growing body of literature advocating for patient-centered care. As this concept gains traction, it may usher in a new era of healthcare delivery that prioritizes patient comfort without sacrificing the quality of medical attention.

In conclusion, the comparative study conducted at a tertiary hospital in Singapore shines a much-needed light on the potential of multidisciplinary hospital-at-home programs. By merging effective medical care with the comfort of home, this innovative approach could reshape how future healthcare is administered, making it more accessible and holistic. As healthcare continues to evolve, embracing new models like this may hold the keys to addressing some of the industry’s most pressing challenges.

Subject of Research: Multidisciplinary Hospital-at-Home Program

Article Title: A Multidisciplinary Hospital-at-Home Program in a Tertiary Singapore Hospital: A Comparative Study

Article References:

Ong, N., Chu, S., Nurjono, M. et al. A Multidisciplinary Hospital-at-Home Program in a Tertiary Singapore Hospital: A Comparative Study.
J GEN INTERN MED (2025). https://doi.org/10.1007/s11606-025-09900-0

Image Credits: AI Generated

DOI: 10.1007/s11606-025-09900-0

Keywords: hospital-at-home, multidisciplinary care, patient satisfaction, healthcare innovation, telemedicine, chronic care management, healthcare costs.

The prevalence of eating disorders has skyrocketed in recent years, with millions affected worldwide. Traditional one-size-fits-all treatment methods have often proven ineffective, prompting researchers and clinicians to seek more nuanced solutions. Precision psychiatry, the emerging scientific discipline that aims to customize medical treatment based on individual variability, may hold the key to revolutionizing the way eating disorders are treated. The work by Obeid and colleagues focuses on the methodological framework necessary for integrating precision psychiatry into clinical practice, emphasizing the paramount importance of personalized treatment strategies.

Central to the researchers’ argument is the understanding that eating disorders are not merely psychological in nature; they also involve metabolic, neurobiological, and genetic factors. By recognizing the multifaceted approaches needed to address these disorders, the authors advocate for an integrative model that incorporates psychiatric evaluation, nutritional intervention, and genetic testing. Such a model allows clinicians to develop a comprehensive picture of the patient’s condition, addressing the underlying issues that contribute to the behavior rather than simply treating the symptoms.

The research highlights the need for data-driven methods to inform treatment decisions. Through advanced algorithms and statistical modeling, clinicians could potentially identify which treatments are more effective for specific subgroups of patients based on their unique genetic markers and psychological profiles. Obeid and colleagues argue that large-scale databases can be instrumental in assembling genetic information, treatment outcomes, and patient profiles, creating a robust repository that future research can utilize.

Furthermore, the authors underscore the significance of incorporating technological advancements in their proposed framework. Digital health tools, including mobile applications and telemedicine platforms, offer a portal through which patients can engage with their treatment, report symptoms, and receive support in real-time. The integration of technology not only personalizes patient experiences but also facilitates continuous monitoring of treatment efficacy, allowing practitioners to adjust strategies promptly and effectively.

In addition to technology, the study points to the necessity of interdisciplinary collaboration. By bringing together experts from diverse fields such as psychiatry, nutrition, genetics, and computer science, the research advocates for a collaborative approach to address the complex nature of eating disorders. This multifaceted teamwork is essential for developing comprehensive treatment plans that consider the varied influences affecting individual patients.

The implications of this research are vast, especially when considering the potential for improved patient outcomes. Tailored treatment plans derived from precision psychiatry could lead to reduced recovery times, lower relapse rates, and better overall health for those suffering from eating disorders. The implications of this shift towards personalization in treatment extend beyond individual recovery; they may also ease the burden on healthcare systems grappling with the high costs associated with chronic eating disorders.

Considerations for future practice also involve ethical ramifications. As precision psychiatry hinges on utilizing personal data, maintaining patient confidentiality and consent becomes paramount. The authors emphasize that mental health professionals must navigate these ethical considerations delicately to foster trust within the therapeutic relationship. Transparency regarding how data is collected and used will be critical in ensuring that patients feel safe and secure in participating in these novel approaches to treatment.

Moreover, the pathway to implementing precision psychiatry in eating disorder treatment is rife with challenges. The authors clearly outline the barriers that lie ahead, including the need for funding to support research and development, regulatory concerns surrounding new treatment modalities, and potential resistance from practitioners accustomed to traditional methods. However, the authors remain optimistic that continued advocacy and engagement within the scientific community will pave the way for broader acceptance and integration of innovative practices.

In summary, the research by Obeid and colleagues serves as a clarion call for the medical community to recognize the transformative potential of precision psychiatry in the treatment of eating disorders. While the study offers a comprehensive overview of existing knowledge, it also outlines the vital steps necessary for translating these insights into practice. The authors encourage ongoing dialogues among researchers, clinicians, and policymakers to foster an environment conducive to innovation and progress.

The journey toward incorporating precision psychiatry into eating disorder treatment is just beginning. Obeid, Lavallée, and Bradley have laid down essential foundations, providing a roadmap for future research that holds promise not only for those suffering from these complex disorders but also for the field of psychiatry as a whole. Their findings could redefine entire paradigms centered around eating disorder treatments, heralding a new era of targeted, individualized care that places patient well-being at its core.

The urgency of these reforms cannot be overstated; with the prevalence of eating disorders intensifying globally, the pressure mounts on the healthcare system to deliver effective, responsive, and personalized treatment solutions. As the dialogue surrounding precision psychiatry continues to evolve, so too does the hope for healing and recovery for countless individuals grappling with the invisible scars of eating disorders.

Through the synthesis of personalized approaches, technology, and interdisciplinary collaboration, future practice in treating eating disorders stands on the threshold of a significant paradigm shift. The ongoing commitment from researchers and practitioners alike will be pivotal in determining the success of this innovative approach, ultimately ensuring that individuals receive the care they deserve.

As we look toward future possibilities, the conversations ignited by this research set the tone for transformative changes in the field of psychiatry and beyond. The integration of precision methods into eating disorder treatment could serve as a groundbreaking model for other mental health conditions, echoing the need for personalized care across various psychiatric landscapes.

Expanding this discourse further can only lead to a richer understanding of not only eating disorders but also the broader implications of precision medicine in mental health. The exploration of these themes will undoubtedly resonate within the scientific community, inspiring ongoing inquiries aimed at unraveling the intricacies of human behavior and mental wellness.

Subject of Research: Precision psychiatry in eating disorders

Article Title: Considerations for informing precision psychiatry in eating disorders: Foundations for future practice.

Article References:

Obeid, N., Lavallée, N., Bradley, A.H.M. et al. Considerations for informing precision psychiatry in eating disorders: Foundations for future practice.
J Eat Disord 13, 162 (2025). https://doi.org/10.1186/s40337-025-01351-6

Image Credits: AI Generated

DOI: 10.1186/s40337-025-01351-6

Keywords: precision psychiatry, eating disorders, personalized treatment, interdisciplinary collaboration, technology in healthcare.